The most anticipated drug launches in 2025

9. Ophthalmology

• Gene therapies: For inherited retinal diseases.
• Dry eye disease: Novel anti-inflammatory treatments.

10. Women’s Health

• Endometriosis: New non-hormonal treatments.
• Menopause therapies: Improved hormone replacement therapies.

 

Key Companies to Watch

• Pfizer, Novartis, Roche, Merck, Johnson & Johnson, AstraZeneca, Gilead, Biogen, Amgen, and Moderna are among the companies likely to launch groundbreaking drugs in 2025.

1. Oncology (Cancer Treatments)

• Next-generation immunotherapies: Drugs targeting novel immune checkpoints or combining multiple mechanisms to treat resistant cancers.
• CAR-T cell therapies: Expanded approvals for new cancer types and improved versions with fewer side effects.
• Targeted therapies: Drugs targeting specific genetic mutations (e.g., KRAS inhibitors, HER2 inhibitors).

2. Neurological Disorders

• Alzheimer’s disease: New disease-modifying therapies targeting amyloid-beta or tau proteins.
• Parkinson’s disease: Innovative treatments to slow disease progression or improve symptoms.
• ALS (Amyotrophic Lateral Sclerosis): Novel therapies addressing genetic and molecular pathways.

3. Rare Diseases

• Gene therapies: One-time treatments for rare genetic disorders (e.g., spinal muscular atrophy, Duchenne muscular dystrophy).
• Enzyme replacement therapies: Improved formulations for lysosomal storage disorders.

4. Cardiovascular Diseases

• Heart failure therapies: New drugs targeting underlying mechanisms like SGLT2 inhibitors or myosin activators.
• PCSK9 inhibitors: Next-generation cholesterol-lowering drugs.

5. Infectious Diseases

• Antiviral therapies: New treatments for emerging viral threats or improved therapies for HIV, hepatitis, and influenza.
• Antibiotics: Novel antibiotics targeting drug-resistant bacteria.

6. Autoimmune Diseases

• Biologics and biosimilars: New treatments for rheumatoid arthritis, lupus, and psoriasis.
• JAK inhibitors: Expanded use in autoimmune conditions.

7. Metabolic Disorders

• Obesity drugs: Next-generation GLP-1 receptor agonists or dual/triple agonists.
• Diabetes therapies: Innovative insulins or oral GLP-1 drugs.

8. Mental Health

• Depression and anxiety: Rapid-acting antidepressants or psychedelic-based therapies.
• Schizophrenia: New antipsychotics with fewer side effects.

9. Ophthalmology

• Gene therapies: For inherited retinal diseases.
• Dry eye disease: Novel anti-inflammatory treatments.

10. Women’s Health

• Endometriosis: New non-hormonal treatments.
• Menopause therapies: Improved hormone replacement therapies.

 

Key Companies to Watch

• Pfizer, Novartis, Roche, Merck, Johnson & Johnson, AstraZeneca, Gilead, Biogen, Amgen, and Moderna are among the companies likely to launch groundbreaking drugs in 2025.